This post is part of a special report, Top Picks for 2010, the 27th annual survey in which TheStockAdvisors.com asks the nation's leading advisors for their single favorite stock for the new year. See all 80 stocks listed here.

"My top stock pick for 2010 is MannKind Corp. (MNKD), which is developing a a novel formulation of inhalable insulin called Afresa," notes Nate Pile.

In his Nate's Notes newsletter, he explains, "I would emphasize that while the stock must be considered speculative until the FDA delivers a ruling in mid-January of next year, I believe the clinical data that has been submitted by the company is likely to warrant approval."

Continue reading Top Picks for 2010: MannKind (MNKD)

Top Picks for 2010: MannKind (MNKD) originally appeared on BloggingStocks on Tue, 05 Jan 2010 14:00:00 EST. Please see our terms for use of feeds.

"In looking for a highly speculative stock for our portfolio, I have settled on MannKind Corp. (NASDAQ: MNKD), a company that is developing an inhaled insulin product," says Nate Pile.

In his growth-oriented Nate's Notes, the advisor cautions, "I believe we are looking at a situation in which we will either lose most of our money, or triple (or better) our investment in a fairly short period of time."

"In a nutshell, the company's near-term fate hinges upon AFRESA, a novel, ultra rapid acting mealtime insulin therapy being studied for use in adult patients with type 1 and type 2 diabetes mellitus for the treatment of hyperglycemia.

"Working against the company is the fact that there has never been an inhaled insulin product approved for commercial use that has worked very well.

Continue reading MannKind: Speculation on inhaled insulin

MannKind: Speculation on inhaled insulin originally appeared on BloggingStocks on Mon, 06 Jul 2009 15:40:00 EST. Please see our terms for use of feeds.